Centralized Pan-Middle East Survey on the Undertreatment of Hypercholesterolemia (CEPHEUS)

This study has been completed.
Sponsor:
Collaborator:
ClinArt Company & Signen Clinical Discoveries
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01025388
First received: December 2, 2009
Last updated: February 7, 2013
Last verified: May 2011

December 2, 2009
February 7, 2013
November 2009
May 2010   (final data collection date for primary outcome measure)
To establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the NCEP ATP III / updated 2004 NCEP ATP III guidelines, overall and by country. [ Time Frame: 6 months- One visit only, no follow up visits. ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01025388 on ClinicalTrials.gov Archive Site
  • The proportion of patients reaching the LDL-C goals according to the NCEP ATP III/updated 2004 NCEP ATP III in the following sub-populations - Primary/secondary prevention patients - Patients with metabolic syndrome (according to NCEP III definition). [ Time Frame: 6 months - One visit only, no follow up visits. ] [ Designated as safety issue: No ]
  • The proportion of patients reaching the LDL-C goals according to the Third Joint European Task Force guidelines / national guidelines, in the following sub-populations:-Primary/secondary prevention patients -Patients with metabolic syndrome. [ Time Frame: 6 months- One visit only, no follow up visits. ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Centralized Pan-Middle East Survey on the Undertreatment of Hypercholesterolemia
Centralized Pan-Middle East Survey on the Undertreatment of Hypercholesterolemia

The purpose of the study is to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the NCEP ATP III/updated 2004 NCEP ATP III guidelines, overall and by country, in the following sub-populations:

  • Primary/secondary prevention patients.
  • Patients with metabolic syndrome (according to NCEP III definition).

In addition, the purpose is to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the Third Joint European Task Force guidelines/national guidelines, in the survey population and in the following sub-populations:

  • Primary/secondary prevention patients.
  • Patients with metabolic syndrome.
Not Provided
Observational
Observational Model: Case-Only
Time Perspective: Cross-Sectional
Not Provided
Retention:   None Retained
Description:

Whole blood

Non-Probability Sample

Subject who visits the primary care clinics, cardiology clinics and internal medicine clinics, and who fulfil the inclusion criteria.

Hypercholesterolemia
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
4053
May 2010
May 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • On lipid-lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks. ·
  • Subject must sign informed consent

Exclusion Criteria:

  • Subjects who are unwilling or unable to provide informed consent.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Saudi Arabia
 
NCT01025388
NIS-SA-CRE-2009/1
No
AstraZeneca
AstraZeneca
ClinArt Company & Signen Clinical Discoveries
Study Chair: Prof. Mohammed Arafah King Khalid University Hospital
Principal Investigator: Dr. Shorook Alherz King Fahad National Guard Hospital
Principal Investigator: Dr. Khalid Alnemer Security Forces Hospital
Principal Investigator: Dr. Hossam Alghetany Soliman Fakieh Hospital
Principal Investigator: Dr. Othman Metwally King Fahad General Hospital
Principal Investigator: Dr. Akram Alkhadra King Fahad University Hospital
Principal Investigator: Dr. Faisal Alanizi Ministry Of Health Saudi Arabia
AstraZeneca
May 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP